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Background: Selective delivery of anticancer agents to target areas in the body is desirable to minimize the side
effects while maximizing the therapeutic efficacy. Anthracycline antibiotics such as doxorubicin (DOX) are widely
used for treatment of a wide variety of solid tumors.
This study evaluated the potential of a polymeric micellar formulation of doxorubicin as a nanocarrier system for
targeted therapy of a folate-receptor positive human ovarian cancer cell in line.
Results: DOX-conjugated targeting and non-targeting micelles prepared by the dialysis method were about 188
and 182 nm in diameter, respectively and their critical micelle concentration was 9.55 μg/ml. The DOX-conjugated
micelles exhibited a potent cytotoxicity against SKOV3 human ovarian cancer cells. Moreover, the targeting micelles
showed higher cytotoxicity than that of non-targeting ones (IC50 = 4.65 μg/ml vs 13.51 μg/ml).
Conclusion: The prepared micelle is expected to increase the efficacy of DOX against cancer cells and reduce its
side effects.
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Anthracycline antibiotics such as doxorubicin are widely
used for treatment of a wide variety of solid tumors and
hematological malignancies [1-3], but their clinical use is
limited by their low water solubility, severe side effects
such as cardiotoxicity and inherent drug resistance [4,5].
Drug delivery systems such as polymeric nanocarriers
[6,7], liposomes [8] and dendrimers [9] can improve the
antitumour efficacy and reduce toxicity of free DOX.
Micelles that consist of hydrophilic shell and hydropho-
bic core are spherical nanoparticulate carriers with
unique properties such as high solubility, high stability,
appropriate size (20–200 nm) and long circulation in
blood [10,11]. The use of polymeric micelles as carriers
of anticancer drugs has been reported in previous studies
[12-16].
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unless otherwise stated.while maximizing the therapeutic efficacy. Non-specific
drug delivery often causes adverse effects on normal
cells. Folate (FOL) has several advantages over various
targeting ligands such as transferrin, peptides and anti-
bodies. FOL has a small size, non-immunogenicity, low
molecular weight and stability [17]. Therefore, micellar
delivery systems have further been modified with target-
specific ligands (FOL) to enhance tumor specificity and
improve the tumor uptake by folate receptor-mediated
endocytosis. Many approaches have also been described
to prepare pH-sensitive micelles that can release the
encapsulated drugs in acidic environment of tumors. Bae
et al. have reported the pH-sensitive polymeric micelles
based on poly (ethylene glycol)-poly(aspartate hydrazone-
adriamycin) for DOX delivery that can release the drug
in response to acidic pH at endosomes (pH 5.0–6.0)
and lysosomes (pH 4.0–5.0). The micelles showed high
antitumor activity in C-26 bearing mice [18]. Folate-poly
(ethylene glycol)-poly (aspartate hydrazone-adriamycin)
micelles For active intracellular drug delivery was also
prepared. The micelles showed good antitumor effect
in KB cell line [17]. In another study, Liua and co-workerstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lacrylamide-co-N,Ndimethylacrylamide-co-2-aminoethyl
methacrylate)-b-poly (10-undecenoic acid) block copoly-
mer and showed that the micelles was able to target the
KB cells and release the drug in acidic pH of the tumor.
The micelles significantly enhanced KB cell growth
inhibition [19].
Covalent conjugation of anticancer drugs to their nano-
particulate carrier is more advantageous than physical
encapsulation of drugs because it helps to stabilize the
drug and prevent premature drug release into the blood
circulation to assure drug delivery into the cancerous
cells. Therefore, in this study, a folate functionalized PLA-
PEG block copolymer was synthesized and doxorubicin
was conjugated to the block copolymer via a pH-sensitive
hydrazone bond. The prepared micelle was characterized
for the structure of prepared block copolymer, average
size and critical micelle concentration (CMC). The
in vitro cytotoxicity of the folate targeting micelle
against SKOV3 human ovarian cancer cells was evaluated
using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltet-
razolium bromide (MTT) assay and compared with the
folate-free micelle. Epithelial cancer cell lines such as
SKOV3 demonstrate overexpression of folate receptors
(FRs) [20]. MTT is a tetrazolium salt, which is reduced
within the mitochondria in metabolically active viable
cells. The resulting formazan crystals are impermeable
to the cell membranes and accumulate only in uninjured
cells [21], therefore this assay provides a measure of




The IR spectra were recorded on a Nicollet FT-IR Magna
550 spectrometer, Madison, USA. The 1H NMR spectrum
was recorded on a Bruker DRX (Avance 500) spectrom-
eter, Rheinstetten, Germany, 500 MHz. A double beam
UV-Visible spectrophotometer (model 2100, Shimadzu,
Japan) was utilized for spectrophotometric measure-
ments. Dynamic light scattering (DLS) (Zetasizer Nano-
ZS, Malvern Instruments Ltd., UK) was used to determine
the dynamic diameter, size distribution and zeta potential
of the micelles.
Materials
Doxorubicin was purchased from RPG Life Sciences limited
(Mumbai, India). L-lactide, poly(ethylene glycol) (PEG)
with MW 4000 g/mol, Hydrazine, N-hydroxysuccinimide
(NHS), dicyclohexylcarbodiimde (DCC), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC ), stannous
octoate, folate and MTT were obtained from Sigma
(St Louis, MO, USA). p-Nitrophenyl chloroformate
(p-NPC), acetonitrile, toluene, dichloromethane andacetone (analytical grade) were purchased from Merck
(Darmstadt, Germany). RPMI 1640 medium and peni-
cillin/streptomycin solution were obtained from Gibco
Invitrogen (Carlsbad, CA, USA). All other chemicals were
of analytical grade.
Preparation of folate-conjugated PLA-PEG block
copolymer by ring opening polymerization
Preparation of PLA-PEG block copolymer containing ter-
minal carboxylate group was started with the synthesis of
monocarboxylated PEG according to the method described
by WH Jo et al. [22] with some modifications and followed
by ring-opening polymerization of the lactide in the
presence of carboxylated PEG [23]. Briefly, vacuum-
dried lactide (16 g) and carboxylated PEG (3 g) were
allowed to react in anhydrous toluene in the presence
of and tin (II) 2-ethylhexanoate (200 mg) as a catalyst
at the refluxing temperature of toluene. The PLA-PEG
copolymer was extracted by chloroform after evaporation
of the reaction solvent. The prepared PLA-PEG–COOH
(1 g) was activated by adding EDC (50 mg) and NHS
(40 mg) in dimethyl sulfoxide (DMSO, 10 ml) 5 h at room
temperature. To prepare the folate-functionalized copoly-
mer, folate-NH2 was synthesized from reaction of folic
acid (250 mg) and triethylamine (TEA, 0.5 ml) in the
presence of NHS and EDC in methanol. After 2 h, 1 ml
of ethylene diamine was added and the reaction continued
overnight at room temperature. The prepared folate-NH2
was added to the activated copolymer in DMSO and the
reaction continued for additional 48 h. The mixture was
then dialyzed against deionized water to remove unreacted
folate-NH2. The formation of monocarboxylated PEG
and PLA-PEG copolymer was confirmed by infrared
(IR) spectroscopy. The conjugation of folate to the co-
polymer was also confirmed by 1H NMR spectroscopy.
The total amount of folate conjugated to copolymer
was determined by UV spectroscopy at 365 nm.
Preparation of doxorubicin-conjugated PLA-PEG block
copolymer and micelle formation
Conjugation of Hydrazone Derivative of doxorubicin (Hyd-
DOX) to the activated PLA-PEG-FOL block copolymer
was carried out according to previously described method
with some modifications [14]. The terminal PLA in copoly-
mer was activated by adding p-NPC (340 mg) and dry pyri-
dine (230 mg) to PLA-PEG-FOL (3 g) in dry methylene
chloride at 0°C, followed by reaction at room temperature
under nitrogen atmosphere. The conjugation of DOX-Hyd
to freeze-dried activated block copolymer was performed in
dry tetrahydrofurane under nitrogen atmosphere for 36 h.
In the final step, dialysis method was employed to prepare
the micelles. The folate-free micelles were also prepared in
a similar way. The doxorubicin content in the copolymer
was measured by UV spectroscopy at 490 nm.
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dynamic light scattering (DLS)
Particle size, polydispersity index (PDI) and zeta potential
of blank and DOX-conjugated polymeric micelles were
measured using a Zetasizer (Nano-ZS, Malvern Instru-
ments Ltd., UK). All measurements were performed in
triplicate.
Determination of the critical micelle concentration (CMC)
The CMC of prepared micelles was estimated by fluores-
cence spectroscopy using pyrene as a fluorescent probe
[24]. Briefly, 10 ml of DOX-conjugated copolymer aque-
ous solutions with different concentrations (0.05 μg/ml to
500 μg/ml) were added to the volumetric flasks containing
solvent-dried pyrene (10−7 M). The solutions were soni-
cated at 40°C for 30 minutes, followed by stirring for 24 h
at room temperature. The excitation wavelength was
set at 334 nm and the intensity ratios of I383 to I372 were
plotted as a function of concentration of the block copoly-
mer solutions. The CMC of DOX-conjugated micelle
was taken from the copolymer concentration at which the
relative fluorescence intensity ratio began to increase.
In vitro cytotoxicity studies
SKOV3 human ovarian cancer cells were cultured
in RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin-streptomycin at
37°C in a humidified incubator with 5% CO2. The
cytotoxic activity of free DOX and chemically conjugated
DOX in targeting (DOX-Hyd-PLA-PEG-FOL) and non-
targeting micelles against SKOV3 cells was measured
using MTT assay. The cells were seeded in 96-well
plates at 10,000 cells per well and incubated for 24 h
before test. Free DOX and DOX-conjugated targeting
and non-targeting PLA-PEG micelles were dissolved
and diluted in the growth medium to give different
concentrations of DOX (equivalent DOX concentrations;Figure 1 Synthesis scheme of DOX-conjugated PLA-PEG diblock copo
(c) and DOX-PLA-PEG-FOL (d).10−2 - 105 ng/ml). The blank micelle concentrations (0.01-
100 μg/ml) in RPMI 1640 were also prepared. The old
media in the plates were replaced with 100 μl of the
media containing the test compounds. After 72 h incu-
bation, 20 μl of MTT solution (5 mg/ml) was added to
each well and the plates were then maintained in incu-
bator for an additional 4 h. The media containing MTT
were then removed and the purple formazan crystals
were dissolved in 100 μl of DMSO. The absorbance of
the formazan crystals was read with a Synergy HT Mi-
croplate Reader (Bio-Tek Instruments, Winooski, VT) at
570 nm. The IC50 values (The concentration of the test
compounds at which 50% cell growth is inhibited) were
calculated by using GraphPad Prism Software (Version
5.04, GraphPad Software, San Diego California, USA).
Data analysis
All experiments were carried out three times and results
were expressed as mean ± SD. All data analyses were
performed using GraphPad Prism version 5.04. The
significance level was set at p < 0.05.
Results and discussion
Preparation of doxorubicin-conjugated PLA-PEG-Folate
micelle
The synthesis pathway of DOX-Hyd-PLA-PEG-FOL is
illustrated in Figure 1. PEG with two different end groups
was first synthesized for the conjugation of folic acid to
the carboxylate terminal group. The polymerization of
lactide was then carried out in the presence of mono-
carboxylated PEG which PLA was conjugated to the
hydroxyl terminal group of PEG. Spectral data of the
prepared compounds are shown in Table 1. The structure
of monocarboxylated PEG and PLA-PEG copolymer were
confirmed by the IR spectrum (Figure 2). The peak at
1708 cm−1 in Figure 2(a) indicates the presence of car-
bonyl group of -COOH in the structure of carboxylatedlymer. Synthesis of PLA-PEG-COOH (a), Folate-NH2 (b), PLA-PEG-FOL
Table 1 Spectral data of the prepared compounds
Compounds IR (KBr) Vmax in cm-1 1H-NMR (CDCl3) δ in ppm
PEG-COOH 1708 (C=O)
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(b)), the characteristic sharp peak at 1755 cm−1 is attrib-
uted to the carbonyl (C =O) group in the PLA block of
PLA-PEG-COOH. Besides, the peaks related to the C-
O-C stretching and C =O of COOH in PEG appeared at
1091 and 1635 cm−1, respectively. The IR spectrum
strongly indicates the ring opening polymerization of
lactide and formation of PLA-PEG block copolymer.
The1H-NMR spectrum (Figure 3) of prepared PLA-PEG
copolymer was used to estimate the average molecular
weight of the copolymer by comparing the peak ratio of
the methylene protons of PEG (−OCH2CH2–: δ 3.6 ppm)
with the peak ratio of methine protons of PLA (CH:δ
5.2 ppm). The molecular weight of PEG was 4000 g/mol,
therefore the molecular weight of PLA-PEG copolymer
was approximately 30,000. From these results, the degree
of polymerization (DP) of lactate, n, is 373. In the next
step, folate-NH2 was synthesized, as shown in Figure 1 and
its conjugation to carboxylate-terminal group of PEG wasFigure 2 FTIR spectra of monocarboxylated PEG (a) and PLA-PEG-COOcarried out after activation of block copolymer. The effect
of reaction solvent and temperature was evaluated in the
synthesis of folate-NH2 and the best results were achieved
at room temperature in methanol solvent. The conjuga-
tion of folate to the copolymer was confirmed by 1H NMR
spectroscopy. The 1H NMR spectrum (Figure 3) shows
the corresponding peaks of folate (small peaks at 7.1 ppm,
8.1 ppm and approximately 1 ppm) and p-nitrophenyl
chloroformate (small peaks at 7.5 ppm and 8.4 ppm).
The molar percent of folate in the copolymer is 66.8%
measured by UV absorbance at 365 nm. The spectrum
also shows the characteristic peaks of PEG (CH2: 3.6 ppm)
and PLA (CH3: 1.6 ppm and CH: 5.2 ppm). To provide
controlled release of doxorubicin, hydrazine was used as
an acid-sensitive linker for DOX conjugation to the PLA
backbone. Compared to the published method by Etrych
et al. [25], the conjugation method was carried out in mild
reaction conditions with a less time consuming and less
costly reaction. The drug-conjugated micelle was preparedH conjugate (b).
Figure 3 1H NMR spectrum of p-nitrophenyl chloroformate-PLA-PEG-FOL (500 MHz, CDCl3).
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the copolymer was 39.6% (molar percent) determined by
UV absorbance at 480 nm.
Particle size distribution
The average diameter and zeta potential data of the
blank, DOX-conjugated targeting and non-targeting poly-
meric micelles in deionized water measured using DLS
technique are listed in Table 2. The mean diameters of
the drug-free PLA-PEG-FOL micelles and the drug-
conjugated targeting and non-targeting micelles were
176.71, 188.43 and 182.19 nm, respectively. In addition,
the polydispersity index values indicate that the formed
micelles had narrow size distribution. The particle size
values were comparable to those obtained for other block
copolymeric micelles with similar molecular weights [26].
In general, the size of nanoparticles affects their in vivo
bio distribution. The size cut-off of tumor vasculature is
about 200–700 nm [27]. The average size of both blank
and DOX-conjugated micelles was smaller than 200 nm;
therefore they are acceptable for drug delivery in cancer
treatment. As presented in Table 2, the zeta potential
values of micelles with folate ligand are more negative
than that of non-targeting micelles which is due to the
negative charged carboxyl groups of the folate ligand [28].Table 2 Particle size, polydispersity index and zeta potential
dialysis method
Zeta potential (mV) Polydispersity
−12.47 ± 2.92 0.25 ± 0.06
−10.24 ± 1.57 0.28 ± 0.04
−7.12 ± 1.23 0.16 ± 0.05
Values are presented as mean ± SD (n = 3).The negative charge enhances the dispersion stability of
the micelles. Since the particle size and surface chemistry
determine the fate of the micelles in blood circulation,
the polymeric micelles prepared in this study may be
appropriate for in vivo applications in cancer therapy.
The CMC of DOX-conjugated PLA-PEG block copolymer
The formation of micelles was studied using the CMC of
DOX-Hyd-PLA-PEG-FOL determined by a fluorescence
spectrophotometer measurement in the presence of pyr-
ene as a fluorescent probe. The intensity ratio of the
third band to the first band of the pyrene emission spectra
(I383/I372) was used to evaluate the polarity of the pyrene
environment [29]. The CMC of DOX-Hyd-PLA-PEG-FOL
was 9.55 μg/ml as derived from Figure 4. Depending on
the copolymer length, the CMC values of PLA-PEG co-
polymer reported in similar studies are 1–100 μg/ml
[30,31]. The low CMC value reported in our study indi-
cates that pyrene is located in a hydrophobic environment
which is due to the relatively high molecular weight of the
PLA backbone in the copolymer. Micelles with low CMC
value exhibit a relative stability upon dilution in vivo [32],
which is true in the case of prepared DOX-Hyd-PLA-PEG-
FOL micelles.of blank and DOX-conjugated micelles prepared by the
Particle size (nm) Micelles
176.71 ± 12.61 Blank micelles
188.43 ± 8.96 DOX-Hyd-PLA-PEG-FOL micelles
182.19 ± 6.38 DOX-Hyd-PLA-PEG micelles
Figure 4 The intensity ratio (I383/I372) of pyrene fluorescence as
a function of DOX-Hyd-PLA-PEG-FOL concentration.
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Figure 5 compared in vitro cytotoxicity of free DOX,
DOX-Hyd-PLA-PEG-FOL micelles and DOX-Hyd-PLA-
PEG micelles against SKOV3 cells as determined by the
MTT assay. All three test compounds decreased the
viability of the cells in a dose-dependent manner. The
IC50 value of DOX, the concentration of DOX at which
50% cell growth is inhibited, was 0.08, 4.65 and 13.51 μg/ml
for free DOX, DOX-conjugated targeting and non-targeting
micelles, respectively. DOX-conjugated targeting micelles
exhibited higher cytotoxicity than that of non-targeting
ones (IC50 = 4.65 μg/ml vs 13.51 μg/ml). The overexpres-
sion of FRs on the surface of SKOV3 cells [33] enhanced
the uptake of the DOX-Hyd-PLA-PEG-FOL micelles
via FR-mediated endocytosis and resulted in 3-fold higher
cytotoxicity. Free DOX also showed higher cytotoxic
activity compared to DOX-conjugated targeting and non-
targeting micelles. The higher cytotoxicity of free DOX
seems to be due to the rapid diffusion of this small
molecule into the cells, while the DOX-conjugated mi-
celles are internalized into the cells via the endocytosisFigure 5 In vitro cytotoxicity of free DOX and DOX-conjugated
targeting/non-targeting micelles against SKOV3 cell line after
72 h measured with the MTT assay. Cell viability is expressed
as mean ± S.D.process. Moreover, the prepared micelles released DOX in
a sustained and controlled manner using the acid labile
hydrazone linkage (data not shown). Some other nanopar-
ticulate delivery systems with sustained drug release also
exhibited a less cytotoxic activity compared to the corre-
sponding free drug [34-37]. It should be noted that the
blank micelles did not show any cytotoxicity against
SKOV3 cells (data not shown). The DOX-conjugated tar-
geting micelles exhibited a potent cytotoxicity against
SKOV3 cells, therefore the DOX-Hyd-PLA-PEG-FOL
micelles can provide an effective treatment for ovarian
cancer.
Conclusions
Doxorubicin-conjugated PLA-PEG-folate micelles with the
hydrazone linkage were prepared with active targeting
capability. This formulation showed a superior cytotoxicity
compared to non-targeting ones against a folate-receptor
positive cell line. The prepared DOX-conjugated micelles
with folate ligand, appropriate size and low CMC value
have a great potential for in vivo applications in cancer
therapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZH: Carried out synthesis studies of block copolymer, micelle preparation
and characterization, In vitro cytotoxicity studies and drafted the manuscript.
MA: Supervisor and participated in polymer synthesis studies and carried out
the interpretation of the NMR data. MGK: Supervisor and participated in
design and interpretation of in vitro cytotoxicity studies. SMR: Supervisor and
participated in the design of the study. KG: Supervisor, conceived of the
study, and participated in its design and coordination and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was financially supported by grant from Research Council of
Tehran University of Medical Sciences grant No.90-02-87-11816.
Author details
1Department of Medical Nanotechnology, School of Advanced Technologies in
Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2Department of
Medicinal Chemistry, Faculty of Pharmacy and Drug Design & Development
Research Center, Tehran University of Medical Sciences, Tehran, Iran.
3Department of Pharmacology, School of Medicine, Tehran University of
Medical Sciences, Tehran, Iran. 4Department of Toxicology & Pharmacology,
Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University
(IAUPS), Tehran, Iran. 5Aerosol Research Laboratory, Department of
Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences,
Tehran, Iran.
Received: 26 November 2013 Accepted: 25 February 2014
Published: 6 March 2014
References
1. Sharpe M, Easthope SE, Keating GM, Lamb HM: Spotlight on polyethylene
glycol-liposomal doxorubicin in solid and hematological malignancies
and AIDS-related Kaposi’s Sarcoma. Am J Cancer 2003, 2:67–72.
2. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF: The distribution of
the anticancer drug doxorubicin in relation to blood vessels in solid
tumors. Clin Cancer Res 2005, 11:8782–8788.
3. Bisht S, Maitra A: Dextran–doxorubicin/chitosan nanoparticles for solid
tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:415–425.
Hami et al. DARU Journal of Pharmaceutical Sciences 2014, 22:30 Page 7 of 7
http://www.darujps.com/content/22/1/304. Horenstein MS, Vander Heide RS, L_Ecuyer TJ: Molecular basis of
anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab
2000, 71:436–444.
5. Orhan B: Doxorubicin cardiotoxicity: growing importance. J Clin Oncol
1999, 17:2294–2296.
6. Minko T, Kopečková P, Kopeček J: Efficacy of the chemotherapeutic action
of HPMA copolymer‐bound doxorubicin in a solid tumor model of
ovarian carcinoma. Int J Cancer 2000, 86:108–117.
7. Dufresne MH, Garrec DL, Sant V, Leroux JC, Ranger M: Preparation and
characterization of water-soluble pH-sensitive nanocarriers for drug
delivery. Int J Pharm 2004, 277:81–90.
8. Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S, Allen TM: Targeted delivery and
triggered release of liposomal doxorubicin enhances cytotoxicity against
human B lymphoma cells. Biochim Biophys Acta 2001, 1515:144–158.
9. Lai PS, Lou PJ, Peng CL, Pai CL, Yen WN, Huang MY, Young TH, Shieh MJ:
Doxorubicin delivery by polyamidoamine dendrimer conjugation and
photochemical internalization for cancer therapy. J Control Release 2007,
122:39–46.
10. Kataoka K, Harada A, Nagasaki Y: Block copolymer micelles for drug
delivery: design, characterization and biological significance. Adv Drug
Delivery Rev 2012, 64:37–48.
11. Hrubý M, Koňák Č, Ulbrich K: Polymeric micellar pH-sensitive drug delivery
system for doxorubicin. J Control Release 2005, 103:137–148.
12. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M,
Okano T, Sakurai Y, Kataoka K: Development of the polymer micelle carrier
system for doxorubicin. J Control Release 2001, 74:295–302.
13. Kohori F, Yokoyama M, Sakai K, Okano T: Process design for efficient and
controlled drug incorporation into polymeric micelle carrier systems.
J Control Release 2002, 78:155–163.
14. Yoo HS, Park TG: Biodegradable polymeric micelles composed of
doxorubicin conjugated PLGA–PEG block copolymer. J Control Release
2001, 70:63–70.
15. Rapoport N, Marin A, Luo Y, Prestwich GD, Muniruzzaman MD: Intracellular
uptake and trafficking of pluronic micelles in drug-sensitive and MDR cells:
effect on the intracellular drug localization. J Pharm Sci 2002, 91:157–170.
16. Lee SC, Kim C, Kwon IC, Chung H, Jeong SY: Polymeric micelles of
poly(2-ethyl-2-oxazoline)-block-poly(q-caprolactone) copolymer as a
carrier for paclitaxel. J Control Release 2003, 89:437–446.
17. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K: Multifunctional
polymeric micelles with folate-mediated cancer cell targeting and pH-
triggered drug releasing properties for active intracellular drug delivery.
Mol Bio Syst 2005, 1:242–250.
18. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K:
Preparation and biological characterization of polymeric micelle drug
carriers with intracellular pH-triggered drug release property: tumor per-
meability, controlled subcellular drug distribution, and enhanced in vivo
antitumor efficacy. Bioconjug Chem 2005, 16:122–130.
19. Liua SQ, Wiradharma N, Gao SJ, Tong YW, Yang YY: Biofunctional micelles
self-assembled from a folate-conjugated block copolymer for targeted
intracellular delivery of anticancer drugs. Biomaterials 2007, 28:1423–1433.
20. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC: Specific targeting of
folate–dendrimer MRI contrast agents to the high affinity folate receptor
expressed in ovarian tumor xenografts. Magn Reson Mater Phys Biol Med
2001, 12:104–113.
21. Knockaert L, Descatoire V, Vadrot N, Fromenty B, Robin MA: Mitochondrial
CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced
by ethanol and acetaminophen. Toxicol In Vitro 2011, 25:475–484.
22. Kim GM, Bae YH, Jo WH: pH‐induced micelle formation of poly
(histidine‐co‐ phenylalanine)‐block‐poly (ethylene glycol) in aqueous
media. Macromol Biosci 2005, 5:1118–1124.
23. Li S, Vert M: Synthesis, characterization, and stereocomplex-induced gelation
of block copolymers prepared by ring-opening polymerization of L
(D)-lactide in the presence of poly (ethylene glycol). Macromolecules 2003,
36:8008–8014.
24. Basu Ray G, Chakraborty I, Moulik SP: Pyrene absorption can be a
convenient method for probing critical micellar concentration (cmc) and
indexing micellar polarity. J Colloid Interface Sci 2006, 294:248–254.
25. Ts E, Šírová M, Starovoytova L, Říhová B, Ulbrich K: HPMA copolymer
conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Mol Pharm 2010, 7:1015–1026.26. Hsiue GH, Wang CH, Lo CL, Wang CH, Li JP, Yang JL: Environmental-sensitive
micelles based on poly (2-ethyl-2-oxazoline)-b-poly (l-lactide) diblock
copolymer for application in drug delivery. Int J Pharm 2006, 317:69–75.
27. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK:
Regulation of transport pathways in tumor vessels: role of tumor type
and microenvironment. Proc Natl Acad Sci U S A 1998, 95:4607–4612.
28. Guo W, Lee RJ: Efficient gene delivery via non-covalent complexes of
folic acid and polyethylenimine. J Control Release 2001, 77:131–138.
29. Wu Y, Li M, Gao H: Polymeric micelle composed of PLA and chitosan as a
drug carrier. Polymers 2008, 2008(16):11–18.
30. Liggins RT, Burt HM: Polyether-polyester diblock copolymers for the
preparation of paclitaxel loaded polymeric micelle formulations.
Adv Drug Deliv Rev 2002, 54:191–202.
31. Yasugi K, Nagasaki Y, Kato M, Kataoka K: Preparation and characterization
of polymer micelles from poly(ethylene glycol)-poly(D, L-lactide) block
copolymers as potential drug carrier. J Control Release 1999, 2:89–100.
32. Kabanov AV, Batrakova EV, Alakhov VY: Pluronic block copolymers as novel
polymer therapeutics for drug and gene delivery. J Control Release 2002,
82:189–212.
33. Bhattacharya R, Patra CR, Earl A, Wang S, Katarya A, Lu L, Kizhakkedathu JN,
Yaszemski MJ, Greipp PR, Mukhopadhyay D: Attaching folic acid on gold
nanoparticles using noncovalent interaction via different polyethylene
glycol backbones and targeting of cancer cells. Nanomedicine 2007,
3:224–238.
34. Alani AW, Bae Y, Rao DA, Kwon GS: Polymeric micelles for the
pH-dependent controlled, continuous low dose release of paclitaxel.
Biomaterials 2010, 31:1765–1772.
35. Xiong XB, Mahmud A, Uludağ H, Lavasanifar A: Multifunctional polymeric
micelles for enhanced intracellular delivery of doxorubicin to metastatic
cancer cells. Pharm Res 2008, 25:2555–2566.
36. Kim JO, Kabanov AV, Bronich TK: Polymer micelles with cross-linked
polyanion core for delivery of a cationic drug doxorubicin. J Control
Release 2009, 138:197–204.
37. Shuai X, Ai H, Nasongkla N, Kim S, Gao J: Micellar carriers based on block
copolymers of poly (ε-caprolactone) and poly (ethylene glycol) for
doxorubicin delivery. J Control Release 2004, 98:415–426.
doi:10.1186/2008-2231-22-30
Cite this article as: Hami et al.: Doxorubicin-conjugated PLA-PEG-Folate
based polymeric micelle for tumor-targeted delivery: Synthesis and
in vitro evaluation. DARU Journal of Pharmaceutical Sciences 2014 22:30.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
